香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年11月4日 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 重要内容提示： * 僅供識別 证券代码：603259 证券简称：药明康德 ...

公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 492,412,308 | RMB | | 1 | RMB | | 492,412,308 | | 增加 / 減少 (-) | | | 18,064,601 | | | | RMB | | 18,064,601 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-071 无锡药明康德新药开发股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）已于 2025 年 10 月 27 日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露《无锡药 明康德新药开发股份有限公司 2025 年第三季度报告》。为了便于广大投资者更全 面深入地了解本公司 2025 年第三季度业绩和经营情况，本公司拟于 2025 年 11 月 12 日（星期三）上午 10:00-11:00 召开业绩说明会，就投资者普遍关心的问题 进行交流。 一、 业绩说明会类型 本次业绩说明会以视频结合网络互动方式召开，本公司将针对 2025 年第三 季度业绩和经营情况与投资者进行交流，并在信息披露允许的范围内就投资者普 遍关注的问题进行回答。 二、 业绩说明会召开的时间、地点 会议召开时间：2025 年 11 月 12 日（星期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 492,412,308 | RMB | | 1 | RMB | | 492,412,308 | | 增加 / 減少 (-) | | | 18,064,601 | | | | RMB | | 18,064,601 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510, ...

该行认为有关股份可能受多个因素影响，包括中美紧张升温，地缘政治风险溢价增加促使投资者获利; 美国《生物安全法案》较温和版本附加至明年《国防授权法》，引发对医药外包服务的不确定性;叠加 美国是否将透过更多监管，如限制中国授权交易或中国来源临床数据，以限制中国生物科技及制药业的 担忧。近期多项授权交易均未提振市场情绪，今年余下时间缺乏强劲产业级正面催化剂，可能限制股价 动能。 该行预期国家医保药品目录价格谈判结果，以及《生物安全法案》立法将影响市场情绪，但产业估值及 对业务发展交易的市场预期正回归更合理水平，亦未见产业坚实基本面出现实质恶化。此次股价回落为 明年表现提供有利条件。该行首选股包括康方生物(09926)、翰森制药(03692)及药明康德（603259） (02359)，亦看好信达生物(01801)及恒瑞医药（600276）(01276)。 摩根大通发布研报称，内地医疗保健股自上月初以来明显回调，恒生医疗保健指数及沪深300医疗保健 指数月内分别下跌12%及9%，对比恒指下跌2%及沪深300指数上涨1%。 ...

该行预期国家医保药品目录价格谈判结果，以及《生物安全法案》立法将影响市场情绪，但产业估值及 对业务发展交易的市场预期正回归更合理水平，亦未见产业坚实基本面出现实质恶化。此次股价回落为 明年表现提供有利条件。该行首选股包括康方生物(09926)、翰森制药(03692)及药明康德(02359)，亦看 好信达生物(01801)及恒瑞医药(01276)。 智通财经APP获悉，摩根大通发布研报称，内地医疗保健股自上月初以来明显回调，恒生医疗保健指数 及沪深300医疗保健指数月内分别下跌12%及9%，对比恒指下跌2%及沪深300指数上涨1%。 该行认为有关股份可能受多个因素影响，包括中美紧张升温，地缘政治风险溢价增加促使投资者获利; 美国《生物安全法案》较温和版本附加至明年《国防授权法》，引发对医药外包服务的不确定性;叠加 美国是否将透过更多监管，如限制中国授权交易或中国来源临床数据，以限制中国生物科技及制药业的 担忧。近期多项授权交易均未提振市场情绪，今年余下时间缺乏强劲产业级正面催化剂，可能限制股价 动能。 ...

Core Insights - The CXO (Contract Research Organization) sector in A-shares shows strong growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters [1] - In the third quarter alone, 21 companies achieved year-on-year revenue growth, driven by international demand for innovative drugs and a supportive policy environment [2] Industry Overview - The innovative drug industry is experiencing a dual boost from policy support and surging demand, which is activating new drug research and development needs, benefiting the CXO sector [2] - The National Healthcare Security Administration and the National Health Commission issued measures to support high-quality development of innovative drugs, proposing 16 policies to enhance the entire chain of support [2] Company Performance - Several CXO companies reported robust order backlogs for the first three quarters. For instance, WuXi AppTec reported a backlog of 59.88 billion yuan, a 41.2% increase year-on-year [2] - Innosilicon reported a nearly 20% increase in order amounts compared to the end of 2024, while Haoyuan reported a 50% year-on-year increase in its small molecule business orders [3] Market Trends - The first half of the year saw a surge in Chinese innovative drugs going global, with total foreign licensing transactions reaching $60 billion, accounting for 99% of global related transactions [3] - Morgan Stanley's healthcare research head in Greater China anticipates stable long-term growth in foreign licensing transactions for Chinese innovative drugs, with multinational companies likely to be more active in acquiring Chinese assets [3] Future Outlook - The CXO industry is expected to benefit from a combination of demand recovery and structural upgrades, with policies, capital, and technology contributing to a more certain industry development [3] - The industry is transitioning from "scale dividends" to "technology premiums," with technological iteration and process innovation becoming the core of competition [3]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

Market Overview - A-shares rebounded in the afternoon on November 3, with all three major indices turning positive by the close; the Shanghai Composite Index rose by 0.55% to 3976.52 points, the Shenzhen Component increased by 0.19% to 13404.06 points, and the ChiNext Index gained 0.29% to 3196.87 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 21.33 billion yuan, a decrease of 2.17 billion yuan from the previous day [1] Sector Performance Coal and Oil - The coal sector saw significant gains, with companies like Antai Group and Zhongmei Energy hitting the daily limit, and others like Shanxi Black Cat and Jin控煤业 rising over 4% [4][6] - The oil sector also performed well, with Huibo Group and Intercontinental Oil hitting the daily limit, and China National Offshore Oil Corporation and China Petroleum rising over 4% [7] AI Applications - The AI application sector was notably active, with stocks like Fushi Holdings and Xinghuan Technology rising over 10%, and several others hitting the daily limit [12][14] Nuclear Power - The nuclear power concept experienced a surge, with significant advancements in thorium-based molten salt reactor technology reported by the Chinese Academy of Sciences, marking a key development in nuclear energy [10] Key Insights - The current prices of thermal coal and coking coal remain at historical lows, providing room for a rebound due to supply-side policies and seasonal demand increases [6] - The "three barrels of oil" (China National Petroleum, Sinopec, and CNOOC) are expected to continue increasing their oil and gas equivalent production, with respective growth rates of 2.6%, 2.2%, and 6.7% projected for the first three quarters of 2025 [7] - The AI-driven content creation market is projected to grow significantly, with over 3000 new works expected in the first half of 2025, indicating a robust demand for AI applications in media [14]

中国经济网北京11月3日讯 药明康德(603259.SH)今日收报96.41元，跌幅3.01%。 西部证券股份有限公司研究员李梦园、徐子悦10月29日发布研报《药明康德(603259)季报点评： 上调全年业绩指引 进一步聚焦主业提升利润率》称，维持"买入"评级。 （责任编辑：徐自立） ...